【靶点聚焦】巨噬细胞：肿瘤免疫新突破点

骨髓单核细胞的功能受到许多负调节剂的严格控制，这些负调节剂直接抑制或转移其效应功能。其中一些分子（例如SIRPα、Siglec和LILRB家族的成员）被称为髓系免疫检查点。这些通路在生理上用于保护宿主组织免受不必要的攻击，导致免疫抑制状态和TAM组织营养功能的激活，最终可能被肿瘤细胞劫持以逃避免疫系统的识别并增殖。

巨噬细胞表达的骨髓检查点和其他抑制性受体

为助力抗体药物开发， ACROBiosystems百普赛斯已成功开发一系列高质量巨噬细胞免疫检查点蛋白，包括CD47、SIRPα、CD24、Siglec-10、LILRBs 等，可用于免疫、抗体筛选、种属交叉等应用场景。

✍ 高纯度经MALS验证

The purity of Biotinylated Human Siglec-10, Fc,Avitag (Cat. No. SI0-H82F6) is more than 90% and the molecular weight of this protein is around 176-216 kDa verified by SEC-MALS.

✍ 高生物活性经ELISA验证

Immobilized Biotinylated Human CD24, Fc,Avitag (Cat. No. CD4-H82F5) at 5 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Anti-CD24 MAb (SN3) with a linear range of 0.6-20 ng/mL (QC tested).

点击申请Protocol

Immobilized Human Siglec-10, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. SI0-H525b) at 5 μg/mL (100 μL/well) can bind Anti-Human Siglec-10 MAb, human IgG with a linear range of 0.6-20 ng/mL (QC tested).

点击申请Protocol

Serial dilutions of Anti-LILRB2 Antibody, Human IgG1 were added into Human LILRB2, Fc Tag (Cat. No. CDD-H5259): Human HLA-G RIIPRHLQL Tetramer Protein (Cat. No. HLG-H52E9) binding reactions. The half maximal inhibitory concentration (IC50) is 0.2403 μg/mL (Routinely tested).

点击申请Protocol

>>>点击查看更多免疫检查点蛋白